6wpt › Citations

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D, Corti D
Nature 583 290-295 (2020)
Related entries: 6wps, 6ws6

Cited: 1122 times
EuropePMC logo PMID: 32422645

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.

Reviews - 6wpt mentioned but not cited (12)

  1. Tackling COVID-19 with neutralizing monoclonal antibodies. Corti D, Purcell LA, Snell G, Veesler D. Cell 184 3086-3108 (2021)
  2. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Yuan M, Liu H, Wu NC, Wilson IA. Biochem Biophys Res Commun 538 192-203 (2021)
  3. Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Trends Pharmacol Sci 41 815-829 (2020)
  4. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. Gavor E, Choong YK, Er SY, Sivaraman H, Sivaraman J. Trends Immunol 41 1006-1022 (2020)
  5. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Papageorgiou AC, Mohsin I. Cells 9 E2343 (2020)
  6. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Valdez-Cruz NA, García-Hernández E, Espitia C, Cobos-Marín L, Altamirano C, Bando-Campos CG, Cofas-Vargas LF, Coronado-Aceves EW, González-Hernández RA, Hernández-Peralta P, Juárez-López D, Ortega-Portilla PA, Restrepo-Pineda S, Zelada-Cordero P, Trujillo-Roldán MA. Microb Cell Fact 20 88 (2021)
  7. Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. Huang Y, Sun H, Yu H, Li S, Zheng Q, Xia N. Antib Ther 3 285-299 (2020)
  8. Man-Specific, GalNAc/T/Tn-Specific and Neu5Ac-Specific Seaweed Lectins as Glycan Probes for the SARS-CoV-2 (COVID-19) Coronavirus. Barre A, Damme EJMV, Simplicien M, Benoist H, Rougé P. Mar Drugs 18 E543 (2020)
  9. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. van der Straten K, van Gils MJ, de Taeye SW, de Bree GJ. Front Med Technol 4 867982 (2022)
  10. Toward rational vaccine engineering. Vishweshwaraiah YL, Dokholyan NV. Adv Drug Deliv Rev 183 114142 (2022)
  11. Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2. Girgis AS, Panda SS, Kariuki BM, Bekheit MS, Barghash RF, Aboshouk DR. Molecules 28 6603 (2023)
  12. Plant Spices as a Source of Antimicrobial Synergic Molecules to Treat Bacterial and Viral Co-Infections. Duarte NBA, Takahashi JA. Molecules 27 8210 (2022)

Articles - 6wpt mentioned but not cited (46)



Reviews citing this publication (259)

  1. Coronavirus biology and replication: implications for SARS-CoV-2. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Nat Rev Microbiol 19 155-170 (2021)
  2. Mechanisms of SARS-CoV-2 entry into cells. Jackson CB, Farzan M, Chen B, Choe H. Nat Rev Mol Cell Biol 23 3-20 (2022)
  3. The biological and clinical significance of emerging SARS-CoV-2 variants. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. Nat Rev Genet 22 757-773 (2021)
  4. Immunological considerations for COVID-19 vaccine strategies. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Nat Rev Immunol 20 615-632 (2020)
  5. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Nat Rev Nephrol 17 46-64 (2021)
  6. COVID-19 diagnosis -A review of current methods. Yüce M, Filiztekin E, Özkaya KG. Biosens Bioelectron 172 112752 (2021)
  7. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. Signal Transduct Target Ther 7 141 (2022)
  8. The first 12 months of COVID-19: a timeline of immunological insights. Carvalho T, Krammer F, Iwasaki A. Nat Rev Immunol 21 245-256 (2021)
  9. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Rev Med Virol 32 e2381 (2022)
  10. COVID-19: Discovery, diagnostics and drug development. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. J Hepatol 74 168-184 (2021)
  11. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. Front Immunol 11 576622 (2020)
  12. Structural biology of SARS-CoV-2 and implications for therapeutic development. Yang H, Rao Z. Nat Rev Microbiol 19 685-700 (2021)
  13. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Heinz FX, Stiasny K. NPJ Vaccines 6 104 (2021)
  14. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, Kwon DH, Singh T, Tilton JC, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. Circ Res 128 1214-1236 (2021)
  15. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, Yu F. Signal Transduct Target Ther 6 233 (2021)
  16. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Datta PK, Liu F, Fischer T, Rappaport J, Qin X. Theranostics 10 7448-7464 (2020)
  17. Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19. Bhalla N, Pan Y, Yang Z, Payam AF. ACS Nano 14 7783-7807 (2020)
  18. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Trougakos IP, Stamatelopoulos K, Terpos E, Tsitsilonis OE, Aivalioti E, Paraskevis D, Kastritis E, Pavlakis GN, Dimopoulos MA. J Biomed Sci 28 9 (2021)
  19. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Sternberg A, Naujokat C. Life Sci 257 118056 (2020)
  20. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Nat Rev Immunol 23 189-199 (2023)
  21. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, Liang KH, Hsieh TY, Wu HC. J Biomed Sci 29 1 (2022)
  22. Structural biology of SARS-CoV-2: open the door for novel therapies. Yan W, Zheng Y, Zeng X, He B, Cheng W. Signal Transduct Target Ther 7 26 (2022)
  23. Monoclonal antibody therapies against SARS-CoV-2. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Lancet Infect Dis 22 e311-e326 (2022)
  24. The glycosylation in SARS-CoV-2 and its receptor ACE2. Gong Y, Qin S, Dai L, Tian Z. Signal Transduct Target Ther 6 396 (2021)
  25. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. Bunders MJ, Altfeld M. Immunity 53 487-495 (2020)
  26. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Pang NY, Pang AS, Chow VT, Wang DY. Mil Med Res 8 47 (2021)
  27. Antibodies and Vaccines Target RBD of SARS-CoV-2. Min L, Sun Q. Front Mol Biosci 8 671633 (2021)
  28. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Yu F, Xiang R, Deng X, Wang L, Yu Z, Tian S, Liang R, Li Y, Ying T, Jiang S. Signal Transduct Target Ther 5 212 (2020)
  29. The humoral response and antibodies against SARS-CoV-2 infection. Qi H, Liu B, Wang X, Zhang L. Nat Immunol 23 1008-1020 (2022)
  30. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Khoury DS, Wheatley AK, Ramuta MD, Reynaldi A, Cromer D, Subbarao K, O'Connor DH, Kent SJ, Davenport MP. Nat Rev Immunol 20 727-738 (2020)
  31. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. Kleanthous H, Silverman JM, Makar KW, Yoon IK, Jackson N, Vaughn DW. NPJ Vaccines 6 128 (2021)
  32. Impact of COVID-19 in solid organ transplant recipients. Danziger-Isakov L, Blumberg EA, Manuel O, Sester M. Am J Transplant 21 925-937 (2021)
  33. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, Ke FY, Su SC, Liang KH, Yuan JP, Chiang HL, Sun CP, Lee IJ, Li WS, Hsieh HP, Tao MH, Wu HC. J Biomed Sci 29 68 (2022)
  34. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, Ferrall L, Hung CF, Wu TC. J Biomed Sci 29 82 (2022)
  35. An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, Guijarro LG, García-Honduvilla N, Asúnsolo A, Bujan J, Monserrat J, Serrano E, Álvarez-Mon M, De León-Luis JA, Álvarez-Mon MA, Ortega MA. Vaccines (Basel) 9 433 (2021)
  36. An update to monoclonal antibody as therapeutic option against COVID-19. Deb P, Molla MMA, Saif-Ur-Rahman KM. Biosaf Health 3 87-91 (2021)
  37. Antibody-mediated neutralization of SARS-CoV-2. Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Immunity 55 925-944 (2022)
  38. SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences. Lotfi M, Rezaei N. J Med Virol 92 1864-1874 (2020)
  39. Antibodies to combat viral infections: development strategies and progress. Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Nat Rev Drug Discov 21 676-696 (2022)
  40. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. Mittal A, Khattri A, Verma V. PLoS Pathog 18 e1010260 (2022)
  41. Viral Emerging Diseases: Challenges in Developing Vaccination Strategies. Trovato M, Sartorius R, D'Apice L, Manco R, De Berardinis P. Front Immunol 11 2130 (2020)
  42. Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production. Zhao X, Chen H, Wang H. Front Mol Biosci 8 629873 (2021)
  43. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. Klasse PJ, Moore JP. Elife 9 e57877 (2020)
  44. SARS-CoV-2 Antiviral Therapy. Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. Clin Microbiol Rev 34 e0010921 (2021)
  45. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand? Chakraborty S, Mallajosyula V, Tato CM, Tan GS, Wang TT. Adv Drug Deliv Rev 172 314-338 (2021)
  46. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Signal Transduct Target Ther 7 202 (2022)
  47. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Zhang L, Guo H. Adv Biomark Sci Technol 2 1-23 (2020)
  48. Current Strategies of Antiviral Drug Discovery for COVID-19. Mei M, Tan X. Front Mol Biosci 8 671263 (2021)
  49. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. Casadevall A, Pirofski LA, Joyner MJ. mBio 12 e03372-20 (2021)
  50. Immune Response and COVID-19: A mirror image of Sepsis. López-Collazo E, Avendaño-Ortiz J, Martín-Quirós A, Aguirre LA. Int J Biol Sci 16 2479-2489 (2020)
  51. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA. Adv Drug Deliv Rev 170 113-141 (2021)
  52. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. Shrestha LB, Tedla N, Bull RA. Front Immunol 12 752003 (2021)
  53. Drug targets for COVID-19 therapeutics: Ongoing global efforts. Saxena A. J Biosci 45 87 (2020)
  54. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski ED, Fera D. Viruses 13 134 (2021)
  55. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. Niu L, Wittrock KN, Clabaugh GC, Srivastava V, Cho MW. Front Immunol 12 647934 (2021)
  56. SARS-CoV-2 reinfection and implications for vaccine development. Nainu F, Abidin RS, Bahar MA, Frediansyah A, Emran TB, Rabaan AA, Dhama K, Harapan H. Hum Vaccin Immunother 16 3061-3073 (2020)
  57. COVID-19: A challenge for electrochemical biosensors. Kudr J, Michalek P, Ilieva L, Adam V, Zitka O. Trends Analyt Chem 136 116192 (2021)
  58. In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives. Sohail MS, Ahmed SF, Quadeer AA, McKay MR. Adv Drug Deliv Rev 171 29-47 (2021)
  59. Glycosylation is a key in SARS-CoV-2 infection. Reis CA, Tauber R, Blanchard V. J Mol Med (Berl) 99 1023-1031 (2021)
  60. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Kim DS, Rowland-Jones S, Gea-Mallorquí E. Front Immunol 11 571481 (2020)
  61. Immunotherapeutic approaches to curtail COVID-19. Owji H, Negahdaripour M, Hajighahramani N. Int Immunopharmacol 88 106924 (2020)
  62. Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review. Jeong GU, Song H, Yoon GY, Kim D, Kwon YC. Front Microbiol 11 1723 (2020)
  63. Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy. Focosi D, Maggi F, Mazzetti P, Pistello M. Rev Med Virol 31 e2170 (2021)
  64. Development and application of therapeutic antibodies against COVID-19. Ning L, Abagna HB, Jiang Q, Liu S, Huang J. Int J Biol Sci 17 1486-1496 (2021)
  65. A global picture: therapeutic perspectives for COVID-19. Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, Apostolopoulos V. Immunotherapy 14 351-371 (2022)
  66. Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses. Siggins MK, Thwaites RS, Openshaw PJM. Trends Microbiol 29 648-662 (2021)
  67. Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. Dubey A, Choudhary S, Kumar P, Tomar S. Curr Microbiol 79 20 (2021)
  68. Two Years into the COVID-19 Pandemic: Lessons Learned. da Silva SJR, do Nascimento JCF, Germano Mendes RP, Guarines KM, Targino Alves da Silva C, da Silva PG, de Magalhães JJF, Vigar JRJ, Silva-Júnior A, Kohl A, Pardee K, Pena L. ACS Infect Dis 8 1758-1814 (2022)
  69. Application of Nanotechnology in the COVID-19 Pandemic. Yang D. Int J Nanomedicine 16 623-649 (2021)
  70. SARS-CoV-2's Variants of Concern: A Brief Characterization. Scovino AM, Dahab EC, Vieira GF, Freire-de-Lima L, Freire-de-Lima CG, Morrot A. Front Immunol 13 834098 (2022)
  71. Antiviral Drug Discovery for the Treatment of COVID-19 Infections. Ng TI, Correia I, Seagal J, DeGoey DA, Schrimpf MR, Hardee DJ, Noey EL, Kati WM. Viruses 14 961 (2022)
  72. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Parray HA, Shukla S, Perween R, Khatri R, Shrivastava T, Singh V, Murugavelu P, Ahmed S, Samal S, Sharma C, Sinha S, Luthra K, Kumar R. Appl Microbiol Biotechnol 105 6315-6332 (2021)
  73. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Al-Kassmy J, Pedersen J, Kobinger G. Viruses 12 E861 (2020)
  74. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. Zhou H, Møhlenberg M, Thakor JC, Tuli HS, Wang P, Assaraf YG, Dhama K, Jiang S. Clin Microbiol Rev 35 e0001422 (2022)
  75. Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application. Zuo W, Zhao X. Clin Immunol 227 108727 (2021)
  76. Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. Sun Y, Ho M. Antib Ther 3 246-256 (2020)
  77. What could explain the late emergence of COVID-19 in Africa? Lalaoui R, Bakour S, Raoult D, Verger P, Sokhna C, Devaux C, Pradines B, Rolain JM. New Microbes New Infect 38 100760 (2020)
  78. A structural view of the SARS-CoV-2 virus and its assembly. Hardenbrook NJ, Zhang P. Curr Opin Virol 52 123-134 (2022)
  79. COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Brüssow H. Microb Biotechnol 15 1927-1939 (2022)
  80. Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance. Chakraborty C, Bhattacharya M, Sharma AR. Curr Opin Pharmacol 62 64-73 (2022)
  81. Harnessing Memory NK Cell to Protect Against COVID-19. Soleimanian S, Yaghobi R. Front Pharmacol 11 1309 (2020)
  82. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. Jaworski JP. Biomed J 44 7-17 (2021)
  83. On the road to ending the COVID-19 pandemic: Are we there yet? Case JB, Winkler ES, Errico JM, Diamond MS. Virology 557 70-85 (2021)
  84. Recent Progress on Polysaccharide-Based Hydrogels for Controlled Delivery of Therapeutic Biomolecules. Rial-Hermida MI, Rey-Rico A, Blanco-Fernandez B, Carballo-Pedrares N, Byrne EM, Mano JF. ACS Biomater Sci Eng 7 4102-4127 (2021)
  85. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, Li SY, Li Y, He YW. Sci China Life Sci 63 1833-1849 (2020)
  86. Big-Data Glycomics: Tools to Connect Glycan Biosynthesis to Extracellular Communication. Kellman BP, Lewis NE. Trends Biochem Sci 46 284-300 (2021)
  87. Drug discovery in the era of cryo-electron microscopy. Robertson MJ, Meyerowitz JG, Skiniotis G. Trends Biochem Sci 47 124-135 (2022)
  88. Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. Chitsike L, Duerksen-Hughes P. Virol J 18 154 (2021)
  89. What do we know about the antibody responses to SARS-CoV-2? Lagunas-Rangel FA, Chávez-Valencia V. Immunobiology 226 152054 (2021)
  90. Markers Associated with COVID-19 Susceptibility, Resistance, and Severity. Fakhroo AD, Al Thani AA, Yassine HM. Viruses 13 E45 (2020)
  91. Nanotechnology for virus treatment. Zhou J, Krishnan N, Jiang Y, Fang RH, Zhang L. Nano Today 36 101031 (2021)
  92. Protective neutralizing epitopes in SARS-CoV-2. Liu H, Wilson IA. Immunol Rev 310 76-92 (2022)
  93. COVID19- clinical presentation and therapeutic considerations. Kenny G, Mallon PW. Biochem Biophys Res Commun 538 125-131 (2021)
  94. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. Ghimire D, Han Y, Lu M. Viruses 14 1255 (2022)
  95. Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. Lee E, Oh JE. Mol Cells 44 392-400 (2021)
  96. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. BioDrugs 36 231-323 (2022)
  97. Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. Zhou QA, Kato-Weinstein J, Li Y, Deng Y, Granet R, Garner L, Liu C, Polshakov D, Gessner C, Watkins S. ACS Pharmacol Transl Sci 3 813-834 (2020)
  98. COVID-19: The Immune Responses and Clinical Therapy Candidates. Zhand S, Saghaeian Jazi M, Mohammadi S, Tarighati Rasekhi R, Rostamian G, Kalani MR, Rostamian A, George J, Douglas MW. Int J Mol Sci 21 E5559 (2020)
  99. Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. Gao K, Wang R, Chen J, Cheng L, Frishcosy J, Huzumi Y, Qiu Y, Schluckbier T, Wei X, Wei GW. Chem Rev 122 11287-11368 (2022)
  100. Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. Pecetta S, Finco O, Seubert A. Semin Immunol 50 101427 (2020)
  101. Recent advances in antibody-based immunotherapy strategies for COVID-19. Esmaeilzadeh A, Rostami S, Yeganeh PM, Tahmasebi S, Ahmadi M. J Cell Biochem 122 1389-1412 (2021)
  102. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Tshiani Mbaya O, Mukumbayi P, Mulangu S. Front Immunol 12 721328 (2021)
  103. Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. Almagro JC, Mellado-Sánchez G, Pedraza-Escalona M, Pérez-Tapia SM. Int J Mol Sci 23 9763 (2022)
  104. Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19. Sharma A, Kontodimas K, Bosmann M. Front Med (Lausanne) 8 648005 (2021)
  105. Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering. Ko S, Jo M, Jung ST. BioDrugs 35 147-157 (2021)
  106. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. Baral PK, Yin J, James MNG. Int J Biol Macromol 186 490-500 (2021)
  107. Antigenic characterization of influenza and SARS-CoV-2 viruses. Wang Y, Tang CY, Wan XF. Anal Bioanal Chem 414 2841-2881 (2022)
  108. Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures. Ghodake GS, Shinde SK, Kadam AA, Saratale RG, Saratale GD, Syed A, Elgorban AM, Marraiki N, Kim DY. Biosens Bioelectron 177 112969 (2021)
  109. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. Kombe Kombe AJ, Zahid A, Mohammed A, Shi R, Jin T. Front Mol Biosci 8 670815 (2021)
  110. Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. Keeler SP, Fox JM. Viruses 13 1037 (2021)
  111. Role of the humoral immune response during COVID-19: guilty or not guilty? Yaugel-Novoa M, Bourlet T, Paul S. Mucosal Immunol 15 1170-1180 (2022)
  112. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. Emrani J, Ahmed M, Jeffers-Francis L, Teleha JC, Mowa N, Newman RH, Thomas MD. Int J Biol Macromol 193 1249-1273 (2021)
  113. Spike protein mediated membrane fusion during SARS-CoV-2 infection. Li X, Yuan H, Li X, Wang H. J Med Virol 95 e28212 (2023)
  114. The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. Waman VP, Sen N, Varadi M, Daina A, Wodak SJ, Zoete V, Velankar S, Orengo C. Brief Bioinform 22 742-768 (2021)
  115. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? Zhang J, Zhang H, Sun L. MAbs 14 2031483 (2022)
  116. Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge. Avery RK. Transplantation 106 1528-1537 (2022)
  117. A molecular understanding of alphavirus entry and antibody protection. Kim AS, Diamond MS. Nat Rev Microbiol 21 396-407 (2023)
  118. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. Cao M, Su X, Jiang S. Stem Cell Reports 16 398-411 (2021)
  119. COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. Ahmad T, Chaudhuri R, Joshi MC, Almatroudi A, Rahmani AH, Ali SM. Front Microbiol 11 588409 (2020)
  120. Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections. Shanmugaraj B, Siriwattananon K, Malla A, Phoolcharoen W. Pathogens 10 1051 (2021)
  121. SARS-CoV-2 cell entry and targeted antiviral development. Chen Z, Du R, Galvan Achi JM, Rong L, Cui Q. Acta Pharm Sin B 11 3879-3888 (2021)
  122. SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion. Quaglia F, Salladini E, Carraro M, Minervini G, Tosatto SCE, Le Mercier P. FEBS J 289 4240-4250 (2022)
  123. The Mechanisms and Animal Models of SARS-CoV-2 Infection. Jia W, Wang J, Sun B, Zhou J, Shi Y, Zhou Z. Front Cell Dev Biol 9 578825 (2021)
  124. The immune system view of the coronavirus SARS-CoV-2. Celardo I, Pace L, Cifaldi L, Gaudio C, Barnaba V. Biol Direct 15 30 (2020)
  125. The role and uses of antibodies in COVID-19 infections: a living review. Scourfield DO, Reed SG, Quastel M, Alderson J, Bart VMT, Teijeira Crespo A, Jones R, Pring E, Richter FC, Oxford-Cardiff COVID-19 Literature Consortium , Burnell SEA. Oxf Open Immunol 2 iqab003 (2021)
  126. 50 Years of structural immunology. Wilson IA, Stanfield RL. J Biol Chem 296 100745 (2021)
  127. Antimicrobial Peptides and Physical Activity: A Great Hope against COVID 19. Laneri S, Brancaccio M, Mennitti C, De Biasi MG, Pero ME, Pisanelli G, Scudiero O, Pero R. Microorganisms 9 1415 (2021)
  128. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Ni Y, Alu A, Lei H, Wang Y, Wu M, Wei X. Mol Biomed 2 1 (2021)
  129. Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development. Cohen SA, Kellogg C, Equils O. Hum Vaccin Immunother 17 84-87 (2021)
  130. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. Winkler MS, Skirecki T, Brunkhorst FM, Cajander S, Cavaillon JM, Ferrer R, Flohé SB, García-Salido A, Giamarellos-Bourboulis EJ, Girardis M, Kox M, Lachmann G, Martin-Loeches I, Netea MG, Spinetti T, Schefold JC, Torres A, Uhle F, Venet F, Weis S, Scherag A, Rubio I, Osuchowski MF. EBioMedicine 66 103291 (2021)
  131. Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. Ezzikouri S, Nourlil J, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Hum Vaccin Immunother 16 2992-3000 (2020)
  132. Glycosylation as a key parameter in the design of nucleic acid vaccines. Ozdilek A, Avci FY. Curr Opin Struct Biol 73 102348 (2022)
  133. Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective. Ajmeriya S, Kumar A, Karmakar S, Rana S, Singh H. J Indian Inst Sci 102 671-687 (2022)
  134. An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks. Kayode AJ, Banji-Onisile FO, Olaniran AO, Okoh AI. Pathogens 10 1108 (2021)
  135. Anti-SARS-CoV-1 and -2 nanobody engineering towards avidity-inspired therapeutics. Obeng EM, Dzuvor CKO, Danquah MK. Nano Today 42 101350 (2022)
  136. Management of COVID-19: current status and future prospects. Kabir MA, Ahmed R, Chowdhury R, Iqbal SMA, Paulmurugan R, Demirci U, Asghar W. Microbes Infect 23 104832 (2021)
  137. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2. Tang Q, Owens RJ, Naismith JH. Viruses 13 2214 (2021)
  138. The development of neutralizing antibodies against SARS-CoV-2 and their common features. Liu LD, Lian C, Yeap LS, Meng FL. J Mol Cell Biol 12 980-986 (2020)
  139. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. Murano K, Guo Y, Siomi H. Biochem Soc Trans 49 2879-2890 (2021)
  140. Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. Sajna KV, Kamat S. Cytotherapy 23 101-110 (2021)
  141. Antibody-mediated immunity to SARS-CoV-2 spike. Errico JM, Adams LJ, Fremont DH. Adv Immunol 154 1-69 (2022)
  142. Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Gunn BM, Bai S. Hum Vaccin Immunother 17 4328-4344 (2021)
  143. Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives. Yayehrad AT, Siraj EA, Wondie GB, Alemie AA, Derseh MT, Ambaye AS. Int J Nanomedicine 16 5713-5743 (2021)
  144. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines. Zhou J, Liu Z, Zhang G, Xu W, Xing L, Lu L, Wang Q, Jiang S. J Med Virol 95 e28172 (2023)
  145. Recent updates on the possible reasons for the low incidence and morbidity of COVID-19 cases in Africa. Tsinda EK, Mmbando GS. Bull Natl Res Cent 45 133 (2021)
  146. SARS-CoV-2-Specific Vaccine Candidates; the Contribution of Structural Vaccinology. Pack SM, Peters PJ. Vaccines (Basel) 10 236 (2022)
  147. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Huang Q, Han X, Yan J. Emerg Microbes Infect 11 2412-2422 (2022)
  148. Three-Dimensional Structures of Carbohydrates and Where to Find Them. Scherbinina SI, Toukach PV. Int J Mol Sci 21 E7702 (2020)
  149. A Review on Currently Available Potential Therapeutic Options for COVID-19. Ohadian Moghadam S. Int J Gen Med 13 443-467 (2020)
  150. Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. Mallano A, Ascione A, Flego M. Int Rev Immunol 41 393-413 (2022)
  151. Broadly neutralizing antibodies against COVID-19. Zhou D, Ren J, Fry EE, Stuart DI. Curr Opin Virol 61 101332 (2023)
  152. Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting. Lim HX, Masomian M, Khalid K, Kumar AU, MacAry PA, Poh CL. Int J Mol Sci 23 4341 (2022)
  153. SARS-CoV-2 biology and host interactions. Steiner S, Kratzel A, Barut GT, Lang RM, Aguiar Moreira E, Thomann L, Kelly JN, Thiel V. Nat Rev Microbiol 22 206-225 (2024)
  154. Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. Rea IM, Alexander HD. Ageing Res Rev 73 101494 (2022)
  155. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. Torresi J, Edeling MA, Nolan T, Godfrey DI. Front Immunol 13 914167 (2022)
  156. Beyond bulk single-chain sequencing: Getting at the whole receptor. Curtis NC, Lee J. Curr Opin Syst Biol 24 93-99 (2020)
  157. Functional nucleic acids as modular components against SARS-CoV-2: From diagnosis to therapeutics. Zhang W, Liu N, Zhang J. Biosens Bioelectron 201 113944 (2022)
  158. Broad-spectrum pan-genus and pan-family virus vaccines. Tan CW, Valkenburg SA, Poon LLM, Wang LF. Cell Host Microbe 31 902-916 (2023)
  159. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Abernathy ME, Dam KA, Esswein SR, Jette CA, Bjorkman PJ. Viruses 13 2106 (2021)
  160. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. Chen J, Huang R, Nie Y, Wen X, Wu Y. Virol Sin 35 713-724 (2020)
  161. Roles of host proteases in the entry of SARS-CoV-2. Zabiegala A, Kim Y, Chang KO. Anim Dis 3 12 (2023)
  162. SARS-CoV-2 spike therapeutic antibodies in the age of variants. Baum A, Kyratsous CA. J Exp Med 218 e20210198 (2021)
  163. COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. Chakravarty S. J Proteome Res 20 139-153 (2021)
  164. Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy. Cheng ZJ, Li B, Zhan Z, Zhao Z, Xue M, Zheng P, Lyu J, Hu C, He J, Chen R, Sun B. Clin Rev Allergy Immunol 64 17-32 (2023)
  165. From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era. Miao G, Chen Z, Cao H, Wu W, Chu X, Liu H, Zhang L, Zhu H, Cai H, Lu X, Shi J, Liu Y, Feng T. Biomed Pharmacother 158 114208 (2023)
  166. State of the art in epitope mapping and opportunities in COVID-19. Hamed SM, Sakr MM, El-Housseiny GS, Wasfi R, Aboshanab KM. Future Sci OA 16 FSO832 (2023)
  167. Structural insights into SARS-CoV-2 infection and therapeutics development. Sun G, Xue L, He Q, Zhao Y, Xu W, Wang Z. Stem Cell Res 52 102219 (2021)
  168. Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. Shirzad M, Nourigorji M, Sajedi A, Ranjbar M, Rasti F, Sourani Z, Moradi M, Mostafa Mir S, Memar MY. Int Immunopharmacol 111 109161 (2022)
  169. The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. Naidoo DB, Chuturgoon AA. Mol Diagn Ther 27 193-226 (2023)
  170. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. Dash P, Mohapatra S, Ghosh S, Nayak B. Front Pharmacol 11 590154 (2020)
  171. A guide to COVID-19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS-CoV-2 infection. Brady DK, Gurijala AR, Huang L, Hussain AA, Lingan AL, Pembridge OG, Ratangee BA, Sealy TT, Vallone KT, Clements TP. FEBS J 291 1632-1662 (2024)
  172. A new dawn for monoclonal antibodies against antimicrobial resistant bacteria. Troisi M, Marini E, Abbiento V, Stazzoni S, Andreano E, Rappuoli R. Front Microbiol 13 1080059 (2022)
  173. An overview of some potential immunotherapeutic options against COVID-19. Bayat M, Asemani Y, Mohammadi MR, Sanaei M, Namvarpour M, Eftekhari R. Int Immunopharmacol 95 107516 (2021)
  174. Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives. Batista CM, Foti L. Int Immunopharmacol 99 108036 (2021)
  175. COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. Mendoza P, Lorenzi JCC, Gaebler C. Curr Opin HIV AIDS 16 25-35 (2021)
  176. COVID-19: Myths and Reality. Kordyukova LV, Shanko AV. Biochemistry (Mosc) 86 800-817 (2021)
  177. Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm. Boni C, Cavazzini D, Bolchi A, Rossi M, Vecchi A, Tiezzi C, Barili V, Fisicaro P, Ferrari C, Ottonello S. Front Immunol 12 730051 (2021)
  178. Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin. Otsubo R, Yasui T. Pharmacol Ther 240 108233 (2022)
  179. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review. Drysdale M, Gibbons DC, Singh M, Rolland C, Lavoie L, Skingsley A, Lloyd EJ. Infection 52 1-17 (2024)
  180. The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. Qiao S, Zhang S, Ge J, Wang X. FEBS Open Bio 12 1602-1622 (2022)
  181. Therapeutic approaches against coronaviruses acute respiratory syndrome. Servidio C, Stellacci F. Pharmacol Res Perspect 9 e00691 (2021)
  182. A Perspective on COVID-19 Management. Pavelić K, Kraljević Pavelić S, Brix B, Goswami N. J Clin Med 10 1586 (2021)
  183. A pocket guide on how to structure SARS-CoV-2 drugs and therapies. Littler DR, MacLachlan BJ, Watson GM, Vivian JP, Gully BS. Biochem Soc Trans 48 2625-2641 (2020)
  184. A study on the effect of natural products against the transmission of B.1.1.529 Omicron. Alkafaas SS, Abdallah AM, Hussien AM, Bedair H, Abdo M, Ghosh S, Elkafas SS, Apollon W, Saki M, Loutfy SA, Onyeaka H, Hessien M. Virol J 20 191 (2023)
  185. Glycan Nanostructures of Human Coronaviruses. Guo W, Lakshminarayanan H, Rodriguez-Palacios A, Salata RA, Xu K, Draz MS. Int J Nanomedicine 16 4813-4830 (2021)
  186. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Zhou D, Zhou R, Chen Z. Immunother Adv 2 ltab027 (2022)
  187. Insight into prognostics, diagnostics, and management strategies for SARS CoV-2. Amara U, Rashid S, Mahmood K, Nawaz MH, Hayat A, Hassan M. RSC Adv 12 8059-8094 (2022)
  188. Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines. Sepand MR, Bigdelou B, Ho JQ, Sharaf M, Lannigan AJ, Sullivan IM, da Silva AP, Barrett LO, McGoldrick S, Lnu Y, Lynch SE, Boisclair JM, Barnard-Pratt DD, Zanganeh S. Antibodies (Basel) 11 35 (2022)
  189. Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development. Suganya S, Divya S, Parani M. Rev Med Virol 31 e2174 (2021)
  190. The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine. Tu JJ, Maksimova V, Ratner L, Panfil AR. Front Microbiol 13 897346 (2022)
  191. A comprehensive review of COVID-19 in India: A frequent catch of the information. Shivangi, Meena LS. Biotechnol Appl Biochem 68 700-711 (2021)
  192. An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies. Francino-Urdaniz IM, Whitehead TA. RSC Chem Biol 2 1580-1589 (2021)
  193. Anti-glycan monoclonal antibodies: Basic research and clinical applications. Gillmann KM, Temme JS, Marglous S, Brown CE, Gildersleeve JC. Curr Opin Chem Biol 74 102281 (2023)
  194. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Ling Z, Yi C, Sun X, Yang Z, Sun B. Sci China Life Sci 66 658-678 (2023)
  195. COVID-19 signalome: Potential therapeutic interventions. Lundstrom K, Hromić-Jahjefendić A, Bilajac E, Aljabali AAA, Baralić K, Sabri NA, Shehata EM, Raslan M, Raslan SA, Ferreira ACBH, Orlandi L, Serrano-Aroca Á, Uversky VN, Hassan SS, Redwan EM, Azevedo V, Alzahrani KJ, Alsharif KF, Halawani IF, Alzahrani FM, Tambuwala MM, Barh D. Cell Signal 103 110559 (2023)
  196. Can anti-parasitic drugs help control COVID-19? Panahi Y, Dadkhah M, Talei S, Gharari Z, Asghariazar V, Abdolmaleki A, Matin S, Molaei S. Future Virol (2022)
  197. Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design. Ghotloo S, Maghsood F, Golsaz-Shirazi F, Amiri MM, Moog C, Shokri F. Rev Med Virol 32 e2347 (2022)
  198. Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic. Siddique R, Bai Q, Shereen MA, Nabi G, Han G, Rashid F, Ahmed S, Benzhanova A, Xue M, Khan S. Hum Vaccin Immunother 17 1113-1121 (2021)
  199. How helpful were molecular dynamics simulations in shaping our understanding of SARS-CoV-2 spike protein dynamics? Abduljalil JM, Elghareib AM, Samir A, Ezat AA, Elfiky AA. Int J Biol Macromol 242 125153 (2023)
  200. Insights of Novel Coronavirus (SARS-CoV-2) disease outbreak, management and treatment. Kumar D, Batra L, Malik MT. AIMS Microbiol 6 183-203 (2020)
  201. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. Feng F, Chen J, Zhao J, Li Y, Li M, Sun C. Viruses 13 2243 (2021)
  202. Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. Pavan M, Moro S. Int J Mol Sci 24 4401 (2023)
  203. Neutralizing and enhancing antibodies against SARS-CoV-2. Liu Y, Arase H. Inflamm Regen 42 58 (2022)
  204. Pandemic strategies with computational and structural biology against COVID-19: A retrospective. Liu CH, Lu CH, Lin LT. Comput Struct Biotechnol J 20 187-192 (2022)
  205. Pharmacotherapeutics of SARS-CoV-2 Infections. Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, Soni D, Das S, Hasan M, Patel M, Senan AM, Gorantla S, McMillan J, Edagwa B, Eisenberg R, Gurumurthy CB, Reid SPM, Punyadeera C, Chang L, Gendelman HE. J Neuroimmune Pharmacol 16 12-37 (2021)
  206. Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine. Thames AH, Wolniak KL, Stupp SI, Jewett MC. ACS Cent Sci 6 1341-1347 (2020)
  207. Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. Li T, Luo KQ. Int J Biol Sci 18 4642-4647 (2022)
  208. The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection. Farouq MAH, Acevedo R, Ferro VA, Mulheran PA, Al Qaraghuli MM. Int J Mol Sci 23 6078 (2022)
  209. The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy. Fertig TE, Chitoiu L, Terinte-Balcan G, Peteu VE, Marta D, Gherghiceanu M. J Cell Mol Med 26 25-34 (2022)
  210. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. Maciorowski D, Ogaugwu C, Durvasula SR, Durvasula R, Kunamneni A. SLAS Discov 26 311-329 (2021)
  211. Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies. Xue JB, Tao SC. Curr Med Sci 41 1065-1074 (2021)
  212. How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response? Pons S, Uhel F, Frapy E, Sérémé Y, Zafrani L, Aschard H, Skurnik D. Stem Cell Rev Rep 19 585-600 (2023)
  213. Immune response and possible therapeutics in COVID-19. Dutta A, Roy A, Roy L, Chattopadhyay S, Chatterjee S. RSC Adv 11 960-977 (2020)
  214. Immunology and controlling of coronaviruses; the current enemy for humanity: A review. Othman SI, Nayel MA, Alwaele MA, Al Fassam H, Abu-Taweel GM, Altoom NG, Almalki AM, Allam AA, Alturki AM, El-Shabasy RM. Int J Biol Macromol 193 1532-1540 (2021)
  215. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19? He X, Zeng XX. Drug Des Devel Ther 16 951-972 (2022)
  216. Neutralizing monoclonal antibodies against highly pathogenic coronaviruses. Xiang R, Wang Y, Wang L, Deng X, Huo S, Jiang S, Yu F. Curr Opin Virol 53 101199 (2022)
  217. Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses. Venkataraman S. Vaccines (Basel) 10 1805 (2022)
  218. Post COVID-19 complications and follow up biomarkers. Abdullah M, Ali A, Usman M, Naz A, Qureshi JA, Bajaber MA, Zhang X. Nanoscale Adv 5 5705-5716 (2023)
  219. Therapeutic antibodies under development for SARS-CoV-2. Ma Z, Zhu M, Zhang S, Qian K, Wang C, Fu W, Lei C, Hu S. View (Beijing) 3 20200178 (2022)
  220. Will Peptides Help to Stop COVID-19? Krut' VG, Chuvpilo SA, Astrakhantseva IV, Kozlovskaya LI, Efimov GA, Kruglov AA, Drutskaya MS, Nedospasov SA. Biochemistry (Mosc) 87 590-604 (2022)
  221. Advances in antibody discovery from human BCR repertoires. Xu Z, Ismanto HS, Zhou H, Saputri DS, Sugihara F, Standley DM. Front Bioinform 2 1044975 (2022)
  222. Application of Pseudotyped Viruses. Cui Q, Huang W. Adv Exp Med Biol 1407 45-60 (2023)
  223. Approaching the Interpretation of Discordances in SARS-CoV-2 Testing. Wontakal SN, Bortz RH, Lin WW, Gendlina I, Fox AS, Hod EA, Chandran K, Prystowsky MB, Weiss LM, Spitalnik SL. Open Forum Infect Dis 8 ofab144 (2021)
  224. Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. Prabhakar PK, Khurana N, Vyas M, Sharma V, Batiha GE, Kaur H, Singh J, Kumar D, Sharma N, Kaushik A, Kumar R. Pharmaceutics 15 451 (2023)
  225. Development of Serological Assays and Seroprevalence Studies of the New Coronavirus 2019 (COVID-19): Reports from Saudi Arabia. Alandijany TA, Faizo AA. Healthcare (Basel) 9 1730 (2021)
  226. Immunological Approaches to the Treatment of New Coronavirus Infection (Review). Lyubavina NA, Saltsev SG, Menkov NV, Tyurikova LV, Plastinina SS, Shonia ML, Tulichev AA, Milyutina MY, Makarova EV. Sovrem Tekhnologii Med 13 81-99 (2021)
  227. Multi-omics for COVID-19: driving development of therapeutics and vaccines. Guo M, Xiong M, Peng J, Guan T, Su H, Huang Y, Yang CG, Li Y, Boraschi D, Pillaiyar T, Wang G, Yi C, Xu Y, Chen C. Natl Sci Rev 10 nwad161 (2023)
  228. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19. Arevalo-Romero JA, Chingaté-López SM, Camacho BA, Alméciga-Díaz CJ, Ramirez-Segura CA. Heliyon 10 e26423 (2024)
  229. On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses. Warger J, Gaudieri S. Viruses 15 70 (2022)
  230. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Focosi D, Casadevall A, Franchini M, Maggi F. Viruses 16 217 (2024)
  231. Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19. Ren Z, Shen C, Peng J. Viruses 15 1297 (2023)
  232. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering. Verkhivker G. Int J Mol Sci 23 2928 (2022)
  233. Advances in understanding the formation and fate of B-cell memory in response to immunization or infection. Kealy L, Good-Jacobson KL. Oxf Open Immunol 2 iqab018 (2021)
  234. Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies. Ziganshina MM, Shilova NV, Khalturina EO, Dolgushina NV, V Borisevich S, Yarotskaya EL, Bovin NV, Sukhikh GT. Viruses 15 1584 (2023)
  235. Can Coronavirus Disease 2019 Effect on Human Reproduction? Abdolrazaghnejad A, Miraj S. Adv Biomed Res 11 55 (2022)
  236. Development of SARS-CoV-2 entry antivirals. Dong M, Galvan Achi JM, Du R, Rong L, Cui Q. Cell Insight 3 100144 (2024)
  237. Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. Gutlapalli SD, Ganipineni VDP, Danda S, Fabian D, Okorie IJ, Paramsothy J, Kailayanathan T, Umyarova R, Aviles C, Garlapati SKP, Ugwendum D, Nfonoyim J. Cureus 15 e36809 (2023)
  238. Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. Kumar S, Dutta D, Ravichandiran V, Sukla S. 3 Biotech 12 227 (2022)
  239. Pharmacologic Treatment and Management of Coronavirus Disease 2019. Shumaker AH, Bhimraj A. Infect Dis Clin North Am 36 349-364 (2022)
  240. Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. Farhangnia P, Dehrouyeh S, Safdarian AR, Farahani SV, Gorgani M, Rezaei N, Akbarpour M, Delbandi AA. Int Immunopharmacol 109 108786 (2022)
  241. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs. Iketani S, Ho DD. Cell Chem Biol 31 632-657 (2024)
  242. Structural understanding of SARS-CoV-2 virus entry to host cells. Le K, Kannappan S, Kim T, Lee JH, Lee HR, Kim KK. Front Mol Biosci 10 1288686 (2023)
  243. The impact of high-resolution structural data on stemming the COVID-19 pandemic. Cox RM, Plemper RK. Curr Opin Virol 49 127-138 (2021)
  244. Web resources facilitate drug discovery in treatment of COVID-19. Mei LC, Jin Y, Wang Z, Hao GF, Yang GF. Drug Discov Today 26 2358-2366 (2021)
  245. [Seroprevalence and SARS-CoV-2 testing in healthcare occupations]. Ziemssen F, Bayyoud T, Bartz-Schmidt KU, Peter A, Ueffing M. Ophthalmologe 117 631-637 (2020)
  246. An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity. Chang-Rabley E, van Zelm MC, Ricotta EE, Edwards ESJ. Vaccines (Basel) 12 675 (2024)
  247. Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents. Chikileva I, Shubina I, Burtseva AM, Kirgizov K, Stepanyan N, Varfolomeeva S, Kiselevskiy M. Biomedicines 10 868 (2022)
  248. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. Radcliffe C, Malinis M, Azar MM. Clin Chest Med 44 279-297 (2023)
  249. COVID-19: from immune response to clinical intervention. Guo ZY, Tang YQ, Zhang ZB, Liu J, Zhuang YX, Li T. Precis Clin Med 7 pbae015 (2024)
  250. Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants. Cui L, Li T, Xue W, Zhang S, Wang H, Liu H, Gu Y, Xia N, Li S. Viruses 16 900 (2024)
  251. Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Zhang T, Yang D, Tang L, Hu Y. Mol Med Rep 30 148 (2024)
  252. Green Synthesis-Mediated Nanoparticles and Their Curative Character Against Post COVID-19 Skin Diseases. Kabeerdass N, Thangaswamy S, Mohanasrinivasan V, Rajasekaran C, Sundaram S, Nooruddin T, Mathanmohun M. Curr Pharmacol Rep 8 409-417 (2022)
  253. Long-Term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics. Sahebkar A, Jamialahmadi T, Rahmoune H, Guest PC. Adv Exp Med Biol 1412 27-49 (2023)
  254. Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases. Schardt JS, Sivaneri NS, Tessier PM. BioDrugs 38 477-486 (2024)
  255. Neutralizing antibodies for SARS-CoV-2 infection. Berenguer J. Rev Esp Quimioter 35 Suppl 3 16-19 (2022)
  256. Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update. Mia ME, Howlader M, Akter F, Hossain MM. Clin Pathol 17 2632010X241263054 (2024)
  257. Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies. Candel FJ, Salavert M, Lorite Mingot D, Manzano Crespo M, Pérez Portero P, Cuervo Pinto R. Rev Esp Quimioter 36 380-391 (2023)
  258. Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. Beeckmans S, Van Driessche E. Front Mol Biosci 8 671923 (2021)
  259. Severe COVID-19: Drugs and Clinical Trials. Ceja-Gálvez HR, Renteria-Flores FI, Nicoletti F, Hernández-Bello J, Macedo-Ojeda G, Muñoz-Valle JF. J Clin Med 12 2893 (2023)

Articles citing this publication (805)



Related citations provided by authors (1)

Quick links